How Cafaro was paid
$17.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| Debra A. CafaroChairman and Chief Executive Officer | $1,162,720 | $12,015,051 | $4,087,303 | $235,999 | $17,501,073 |
| Robert F. ProbstExecutive Vice President and Chief Financial Officer | $727,075 | $3,922,865 | $1,775,186 | $37,095 | $6,462,221 |
| Peter J. BulgarelliExecutive Vice President, Outpatient Medical and Research, Ventas, Inc. | $620,800 | $2,512,111 | $1,015,763 | $31,953 | $4,180,627 |
| J. Justin HutchensExecutive Vice President, Senior Housing and Chief Investment Officer | $715,050 | $3,857,945 | $1,745,826 | $30,809 | $6,349,630 |
| Carey S. RobertsExecutive Vice President, General Counsel, Ethics & Compliance Officer and Corporate Secretary | $594,046 | $2,403,777 | $1,164,942 | $27,084 | $4,189,849 |
What changed and why
- $17.5MDebra A. Cafaro received total compensation of $17,501,073 in fiscal 2025, representing an increase from the prior year total of $14,438,118.
- 35%Total shareholder return exceeded 35% in 2025, significantly outperforming the Nareit Health Care and MSCI U.S. REIT indices.
- 9%Normalized FFO per share grew approximately 9% to $3.48 compared to the prior year.
- 88%The advisory say-on-pay proposal received over 88% support of votes cast at the 2025 annual meeting.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.